Compare Hilton Hotels Corporation Common Stock (HLT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Recursion Pharmaceuticals Inc — how do they compare? Hilton Hotels Corporation Common Stock trades at $327.15 (market cap $72.76B), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 34× Recursion Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| HLT | RXRX | |
|---|---|---|
Market Cap | $72.76B | $2.14B |
Volume | 1,148,634 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $6.79 |
52-Week Low | $256.96 | $2.84 |
Typical Hold Time | 138 Days | 23 Days |
Enterprise Value | $85.78B | $1.66B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $326.56, up 1.89% with a bullish technical outlook. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has been steady, reaching $12.04B in 2025, though valuation multiples like P/E of 47.47 appear elevated. Analyst consensus is strongly positive with 57% buy ratings and a $348.11 price target, while institutional investors have been increasing positions.
The outlook remains favorable given Hilton's strong brand positioning and global travel recovery, but risks include high debt levels and sensitivity to economic cycles. With technical indicators bullish and fundamental growth intact, HLT offers growth potential though current valuation requires careful monitoring of earnings delivery.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
